EGO Stock DD Eldorado Gold Corporation 08/14/2014 19:52:09

New Post Public Reply Private Reply Replies (0) Message Board

Aug 14, 2014 at 8:52 PM

EGO Eldorado Gold Corporation $EGO Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=EGO&...mp;yt0=Go!

Last Updated: 08/14/2014 19:52:04

Current Price and Quotes
Last Price 8.37
Previous Close 8.51 Open 8.50
Daily Range 8.30 - 8.60 52wk Range 5.35 - 9.59
Volume 4,014,378 Dividend 0.0183
Average Vol (30d) 3,918,503 Yield 0.218638

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 1,123,992 1,147,541 1,103,737 791,175
Cost of Revenue 630,960 541,475 468,898 385,131
Gross Profit 493,032 606,066 634,839 406,044
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 90,261 93,829 81,049 85,885
Non-Recurring Items 843,100 60,768 30,773 1,335
Other - - - 107,157
Operating Income (447,128) 454,249 517,650 316,112
Income From Continuing Operations

Add'l Income/Expense Items (24,512) 1,848 (4,876) 14,662
Earnings Before Interest and Tax (464,841) 453,317 518,141 333,486
Interest Expense 40,412 6,983 5,331 8,089
Earnings Before Tax (505,253) 446,334 512,810 325,397
Income Tax 144,362 128,276 165,587 86,939
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (649,615) 318,058 347,223 238,458
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (649,615) 318,058 347,223 238,458
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (649,615) 318,058 347,223 238,458

Recent News

Jul 31, 2014 Eldorado Gold Corporation: 2014 Second Quarter Financial and Operating Results
Jul 28, 2014 Gold Stocks on our Scanner -- Yamana Gold, IAMGOLD, Newmont Mining, Eldorado Gold, and Goldcorp
Jul 7, 2014 Acquisition, Upcoming Earnings and Conference Calls, Sale Completion, and Exploration Updates - Analyst Notes on FM O&G, Royal Gold, Eldorado, AngloGold Ashanti and IAMGOLD
Jun 26, 2014 Eldorado Gold Announces Receipt of the Kisladag Expansion EIA
Jun 26, 2014 Eldorado Gold Corporation: Q2 2014 Financial and Operating Results Release Date and Conference Call
Jun 24, 2014 Metals and Mining Equities Coverage -- Research on Agnico Eagle Mines, B2Gold, Eldorado Gold, and Gold Fields
May 28, 2014 Technical Analysis on Metals and Mining Equities -- Research on Newmont Mining, Goldcorp, Eldorado Gold, and Gold Fields

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...